Publications - 2004 and beyond
Du H, Tardiff DF, Moore MJ and Rosbash M. (2004) Effects of the U1C L13 mutations and temperature regulation of yeast commitment complex formation. Proc. Natl. Acad. Sci. U.S.A. 101: 14841-14846.
Shibuya T, Tange T, Sonenberg N and Moore MJ. (2004) eIF4AIII binds spliced mRNA in the exon junction complex and is essential for nonsense-mediated decay. Nature Structural and Molecular Biology 11:346-351.
Tange TO, Nott A and Moore MJ. (2004) The ever-increasing complexities of the exon Junction complex. Current Opinion in Cell Biology 16: 279-284.
Jurica MS, Sousa D, Moore MJ and Grigorieff N. (2004) Three-dimensional structure of C complex spliceosomes by electron microscopy. Nature Structural and Molecular Biology Vol. 11, March.
Nott A, LeHir H and Moore MJ. (2004) Splicing enhances translation in mammalian cells: An additional function of the exon junction complex. Genes and Development (Cold Spring Harbor Laboratory Press) 18: 210-222.
Jurica MS and Moore MJ. (2003) Pre-mRNA Splicing: Awash in a Sea of Proteins. Molecular Cell Vol. 12, 5-14 July.
LeHir LH, Nott A and Moore MJ. (2003) How introns influence and enhance eukaryotic gene expression. TIBS Vol. 28, No. 4 April.
Nott A, Meislin SH and Moore MJ. (2003) A quantitative analysis of intron effects on mammalian gene expression. RNA 9: 607-617.
Moore MJ. (2002) RNA events. No end to nonsense. Science 298:370-371.
Reichert VL, LeHir LH, Jurica MS and Moore MJ. (2002) 5’ exon interactions within the human spliceosome establish a framework for exon junction complex structure and assembly. Genes and Development (Cold Spring Harbor Laboratory Press) 16: 2778-2791.
Jurica MS and Moore MJ. (2002). Capturing splicing complexes to study structure and mechanism. Methods 28: 336-345.
Jurica MS, Licklider LJ, Gygi SP, Grigorieff N and Moore MJ. (2002) Purification and characterization of native spliceosomes suitable for three-dimensional structural analysis. RNA 8: 426-439.
Moore M.J. (2002) Nuclear RNA Turnover. Cell Vol. 108, 431-434, February 22.
Moore MJ and Roshbash M. (2001). TAPping into RNA export. Science 294: 1841-1842.
LeHir LH, Gatfield D, Izaurralde E and Moore, MJ. (2001) The exon-exon junction complex provides a binding platform for factors involved in mRNA export and nonsense-mediated mRNA decay. The EMBO JournalVol. 20 No. 17, 4987-4997, September.
Mühlemann MC, Mock-Casagrande CS, Wang L, Li S, Custódio CF, Carmo-Fonseca M, Wilkinson MF and Moore MJ. (2001) Precursor RNAs Harboring Nonsense Codons Accumulate Near the Site of Transcription. Molecular Cell Vol. 8, 33-44, July.
LeHir LH, Izaurralde E, Maquat LE and Moore, MJ. (2000) The spliceosome deposits multiple proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. The EMBO Journal Vol. 19 No. 24, 6860-6869.
Bar-Shalom A and Moore MJ. (2000) A Tri-Partite Assay for Studying Exon Ligation by the ai5y Group II Intron. BiochemistryVol. 39 No. 33, 10207-10218 American Chemical Society.
LeHir LH, Moore MJ and Maquat LE. (2000) Pre-mRNA splicing alters mRNP composition evidence for stable association of proteins at exon-exon junctions. Genes and Development (Cold Spring Harbor Laboratory Press) 14: 1098-1109.
Anderson K and Moore MJ. (2000) Bimolecular exon ligation by the human spliceosome bypasses early 3’ splice site AG recognition and requires NTP hydrolysis. RNA 6: 16-25.
Chen S, Anderson K and Moore MJ. (2000) Evidence for a linear search in bimolecular 3’ splice site AG selection. PNAS Vol. 97 No. 2, 593-598 January 18.
Reichert VL and Moore, MJ. (2000) Better conditions for mammalian in vitro splicing provided by acetate and glutamate as potassium counterions. Nucleic Acids Research Vol. 28 No. 2.
Moore, MJ. (2000) Intron recognition comes of AGe. Nature Structural Biology Vol. 7 No. 1, January.
Moore MJ and Query CC. (2000) Joining of RNAs by splinted ligation. Methods in Enzymology 317: 109-123.
1999 - 1990
Luo HR, Moreau GA, Levin N and Moore MJ. (1999) The human Prp8 protein is a component of oth U2- and U12-dependent spliceosomes. RNA, 5: 893-908.
Moore MJ and Query, CC (1999) Preparation of site-specifically modified RNA using T4 DNA ligase. In Methods in Molecular Biology Vol. 118: RNA-Protein Interaction Protocols (Haynes SB, Ed.) Humana Press, pp. 11-19.
Reyes JL, Gustafson EH, Luo HR, Moore MJ and Konarska MM. (1999) The C-terminal region of hPrp8 interacts with the conserved GU dinucleotide at the 5' splice site. RNA 5: 167-179.
Zimmermann RA, Gait MJ and Moore MJ. (1998) Incorporation of modified nucleotides into RNA for studies on RNA structure, function and intermolecular interactions. In Modification and Editing of RNA: The Alteration of RNA Structure and Function. (Grosjean H and BenneR, Eds.) ASM Press, pp. 59-84.
Moore MJ and Query CC. (1998) Uses of site-specifically modified RNAs constructed by RNA ligation. In RNA-Protein Interactions: A Practical Approach. (Smith CWJ, Ed.) Oxford University Press, New York, pp 75-108.
Anderson K and Moore MJ. (1997) Bimolecular exon ligation by the human spliceosome. Science 276: 1712-1716.
Moore MJ. (1996) When the junk isn't junk. Nature379:402-403.
Hinz M, Moore MJ and Bindereif A. (1996) Domain analysis of human U5 RNA: cap trimethylation, protein binding and spliceosome assembly. J. Biol. Chem. 271: 19001-19007.
Moore MJ. (1995) Exploration by lamp light. Nature 374: 766-767.
Query CC, Moore MJ and Sharp PA. (1994) Branch nucleophile selection in pre-mRNA splicing: evidence for the bulged duplex model. Genes Dev. 8:587-597.
Moore MJ, Query CC and Sharp PA. (1993) Splicing of precursors to messenger RNAs by the spliceosome. In The RNA World(Gestland and Atkins, Eds.) Cold Spring Harbor Press, pp. 303-357.
Moore MJ and Sharp PA. (1993) Evidence for two active sites in the spliceosome provided by stereochemistry of pre-mRNA splicing. Nature365: 364-368.
Moore MJ and Sharp PA. (1992) Site-specific modification of pre-mRNA: the 2'-hydroxyl groups at the splice sites. Science 256: 992-997.
Moore MJ, Miller SM and Walsh, CT. (1992) C-terminal cysteines of Tn501 mercuric ion reductase. Biochemistry 31: 1677-1685.
Miller SM, Massey V, Williams CH Jr, Ballou DP, Walsh CT and Moore M. (1991) Communication between the Active Sites in Dimeric Mercuric Reductase: An Alternating Sites Hypothesis for Catalsis. ibid., pp. 2600-2612.
Schiering N, Fritz-Wolf K, Kabsch W, Moore MJ, Distefano MD, Walsh CT and Pai EF. (1991) The three-dimensional structure of mercuric ion reductase from Bacillus sp. strain RC607 Flavins and Flavoproteins: Proceedings of the Tenth International Symposium (Walter de Gruyter, Berlin), pp. 615-625.
Schiering N, Kabsch W, Moore MJ, Distefano MD, Walsh CT and Pai EF. (1991) Structure of the detoxification catalyst mercuric ion reductase from Bacillus sp. strain RC607. Nature352: 168-172.
Moore MJ, Distefano MD, Zydowsky LD, Cummings RT and Walsh CT. (1990) Organomercurial lyase and mercuric ion reductase: nature's mercury detoxification catalysts. Accounts Chem Res.23:301-308.
Miller SM, Massey V, Ballou D, Williams CH Jr., Distefano MD, Moore MJ and Walsh CT. (1990) Use of a site-directed triple mutant to trap intermediates: demonstration that the flavin C(4a)-thiol adduct and reduced flavin are kinetically competent intermediates in mercuric ion reductase. Biochemistry 29: 2831-2841.
Distefano MD, Moore MJ and Walsh CT. (1990) Active site of mercuric reductase resides at the subunit interface and requires cys135 and cys140 from one subunit and cys558 and cys559 from the adjacent subunit: evidence from in vivo and in vitro heterodimer formation. Biochemistry 29:2703-2713.
1989 – 1881
Moore MJ, Distefano MD, Walsh CT, Schiering N and Pai EF. (1989) Purification, crystallization, and preliminary X-ray diffraction studies of the flavoenzyme mercuric ion reductase from Bacillus sp. strain RC607. J. Biol. Chem. 264:14386-14388.
Miller SM, Moore MJ, Massey V, Williams CH Jr, Distefano MD, Ballou DP and Walsh CT. (1989) Evidence for the participation of cys558 and cys559 at the active site of mercuric reductase. Biochemistry28:1194-1205.
Moore MJ and Walsh CT. (1989) Mutagenesis of the N- and C-terminal cysteine pairs of Tn501 mercuric reductase: consequences for bacterial detoxification of mercurials. Biochemistry 28:1183-1194.
Wang Y, Moore MJ, Levinson HS, Silver SS, Walsh CT and Mahler I. (1989) Nucleotide sequence of a chromosomal mercury resistance determinant cloned from a Bacillus sp. with broad-spectrum mercury resistance. J. Bacteriology 171:83-92.
Walsh C, Distefano M and Moore M. (1988) Mutagenesis of paired cysteine residues in the disulfide-containing flavoprotein mercuric ion reductase from mercury-resistant bacteria. Biochem. Soc. Trans.16: 90-91.
Massey V, Miller SM, Ballou DP, Williams CH Jr, Moore M, Distefano M and Walsh CT. (1988) Studies on the active site of mercuric reductase employing site-directed mutants and the thiol-reactive flavin, 6-SCN-FAD. ibid., pp.41-44.
Miller SM, Massey V, Ballou DP, Williams CH Jr, Moore M and Walsh CT. (1988) Reduced forms of native mercuric ion reductase and their reactions with mercuric compounds - activity vs. inactivation. ibid., pp. 29-32.
Moore MJ, Distefano M, Walsh C, Miller S, Williams CH Jr and Ballou D. (1988) The penultimate cysteines in mercuric ion reductase aid in the reduction of mercury. ibid., pp. 37-40.
Walsh CT, Moore MJ and Distefano MD. (1988) Conserved cysteine pairs of mercuric ion reductase: an investigation of function via site-directed mutagenesis. In Flavins and Flavoproteins: Proceedings of the Ninth International Symposium (Walter de Gruyter, New York), pp. 13-24.
Walsh CT, Distefano MD, Moore MJ, Shewchuk LM and Verdine GL. (1988) Molecular basis of bacterial resistance to organomercurial and inorganic mercuric salts. FASEB J. 2:124-130.
Walsh C, Distefano M and Moore M. (1987) Catalytic effects of mutagenesis of paired cysteine residues in the bacterial enzyme mercuric ion reductase. In Protein Structure, Folding and Design 2, Proceedings of UCLA Symposia on Molecular and Cellular Biology, New Series (Alan R. Liss Inc.), pp. 281-292.
Reigle TG, Wilhoit CS and Moore MJ. (1981) Analgesia and increases in limbic and cortical MOPEG-sulfate produced by periaqueductal gray injections of morphine. J. Pharm. Pharmacol. 34: 496-500.